nach oben

Erschienen in:

01.12.2008 | Review

Clinical impact of natural killer cell reconstitution after allogeneic hematopoietic transplantation

verfasst von: Andrea Velardi, Loredana Ruggeri, Antonella Mancusi, Emanuela Burchielli, Katia Perruccio, Franco Aversa, Massimo F. Martelli, on behalf of the Immunobiology Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

Erschienen in: Seminars in Immunopathology | Ausgabe 4/2008

Einloggen, um Zugang zu erhalten

Abstract

Although the optimal donor for allogeneic hematopoietic stem cell transplantation is a human leukocyte antigen (HLA)-matched sibling, 75% of patients do not have a match and alternatives are matched unrelated volunteers, unrelated umbilical cord blood units, and full HLA-haplotype-mismatched family members. This review will focus on the open issues of allogeneic hematopoietic transplantation and on the benefits of natural killer (NK) cell alloreactivity and its underlying mechanisms. Donor-versus-recipient NK cell alloreactivity derives from a mismatch between inhibitory receptors for self major histocompatibility complex (MHC) class I molecules on donor NK clones and the MHC class I ligands on recipient cells. These NK clones sense the missing expression of the self MHC class I allele on the allogeneic targets (“missing self”) and mediate alloreactions. Here, we review the translation of NK cell allorecognition into the clinical practice of allogeneic hematopoietic transplantation and discuss how it has opened innovative perspectives in the cure of leukemia.

Anasetti C, Velardi A (2003) Hematopoietic cell transplantation from HLA partially matched related donors. In: Blume K, Forman S, Appelbaum F (eds) Hematopoietic cell transplantation. Blackwell Science, Malden

Atkinson K, Fibbe W, Champlin R, Ljungman L, Ritz J, Brenner M (2004) Clinical bone marrow and blood stem cell transplantation, 3rd edn. Cambridge University Press, Cambridge

Copelan EA (2006) Hematopoietic stem-cell transplantation. N Engl J Med 354:1813–1826. doi:10.1056/NEJMra052638 PubMedCrossRef

Kolb HJ, Schmid C, Barrett AJ, Schendel DJ (2004) Graft-versus-leukemia reactions in allogeneic chimeras. Blood 103:767–776. doi:10.1182/blood-2003-02-0342 PubMedCrossRef

Ferrara J, Cooke K, Deeg J (2004) Graft vs host disease, 3rd edn. Marcel Dekker, New York

Goulmy E, Schipper R, Pool J, Blokland E, Falkenburg JH, Vossen J, Gratwohl A, Vogelsang GB, van Houwelingen HC, van Rood JJ (1996) Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 334:281–285. doi:10.1056/NEJM199602013340501 PubMedCrossRef

Wang W, Meadows LR, den Haan JM, Sherman NE, Chen Y, Blokland E, Shabanowitz J, Agulnik AI, Hendrickson RC, Bishop CE et al (1995) Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. Science 269:1588–1590. doi:10.1126/science.7667640 PubMedCrossRef

Goulmy E (1997) Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunol Rev 157:125–140. doi:10.1111/j.1600-065X.1997.tb00978.x PubMedCrossRef

Mutis T, Goulmy E (2002) Hematopoietic system-specific antigens as targets for cellular immunotherapy of hematological malignancies. Semin Hematol 39:23–31. doi:10.1053/shem.2002.29248 PubMedCrossRef

10.

Spierings E, Goulmy E (2005) Expanding the immunotherapeutic potential of minor histocompatibility antigens. J Clin Invest 115:3397–3400. doi:10.1172/JCI27094 PubMedCrossRef

11.

Szydlo R, Goldman JM, Klein JP, Gale RP, Ash RC, Bach FH, Bradley BA, Casper JT, Flomenberg N, Gajewski JL, Gluckman E, Henslee-Downey PJ, Hows JM, Jacobsen N, Kolb HJ, Lowenberg B, Masaoka T, Rowlings PA, Sondel PM, van Bekkum DW, van Rood JJ, Vowels MR, Zhang MJ, Horowitz MM (1997) Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol 15:1767–1777PubMed

12.

Petersdorf E, Anasetti C, Martin PJ, Woolfrey A, Smith A, Mickelson E, Malkki M, Lin MT, Hansen JA (2001) Genomics of unrelated-donor hematopoietic cell transplantation. Curr Opin Immunol 13:582–589. doi:10.1016/S0952-7915(00)00263-6 PubMedCrossRef

13.

Petersdorf EW, Hansen JA, Martin PJ, Woolfrey A, Malkki M, Gooley T, Storer B, Mickelson E, Smith A, Anasetti C (2001) Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. N Engl J Med 345:1794–1800. doi:10.1056/NEJMoa011826 PubMedCrossRef

14.

Petersdorf EW, Gooley TA, Anasetti C, Martin PJ, Smith AG, Mickelson EM, Woolfrey AE, Hansen JA (1998) Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood 92:3515–3520PubMed

15.

Sasazuki T, Juji T, Morishima Y, Kinukawa N, Kashiwabara H, Inoko H, Yoshida T, Kimura A, Akaza T, Kamikawaji N, Kodera Y, Takaku F (1998) Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program. N Engl J Med 339:1177–1185. doi:10.1056/NEJM199810223391701 PubMedCrossRef

16.

Hurley CK, Baxter Lowe LA, Logan B, Karanes C, Anasetti C, Weisdorf D, Confer DL (2003) National marrow donor program HLA-matching guidelines for unrelated marrow transplants. Biol Blood Marrow Transplant 9:610–615. doi:10.1016/j.bbmt.2003.08.009 PubMedCrossRef

17.

Saarinen-Pihkala UM, Gustafsson G, Ringden O, Heilmann C, Glomstein A, Lonnerholm G, Abrahamsson J, Bekassy AN, Schroeder H, Mellander L (2001) No disadvantage in outcome of using matched unrelated donors as compared with matched sibling donors for bone marrow transplantation in children with acute lymphoblastic leukemia in second remission. J Clin Oncol 19:3406–3414PubMed

18.

La Nasa G, Giardini C, Argiolu F, Locatelli F, Arras M, De Stefano P, Ledda A, Pizzati A, Sanna MA, Vacca A, Lucarelli G, Contu L (2002) Unrelated donor bone marrow transplantation for thalassemia: the effect of extended haplotypes. Blood 99:4350–4356. doi:10.1182/blood.V99.12.4350 PubMedCrossRef

19.

Eapen M, Rubinstein P, Zhang MJ, Camitta BM, Stevens C, Cairo MS, Davies SM, Doyle JJ, Kurtzberg J, Pulsipher MA, Ortega JJ, Scaradavou A, Horowitz MM, Wagner JE (2006) Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 months. J Clin Oncol 24:145–151. doi:10.1200/JCO.2005.02.4612 PubMedCrossRef

20.

Gluckman E, Broxmeyer HA, Auerbach AD, Friedman HS, Douglas GW, Devergie A, Esperou H, Thierry D, Socie G, Lehn P et al (1989) Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med 321:1174–1178PubMed

21.

Wagner JE, Barker JN, DeFor TE, Baker KS, Blazar BR, Eide C, Goldman A, Kersey J, Krivit W, MacMillan ML, Orchard PJ, Peters C, Weisdorf DJ, Ramsay NK, Davies SM (2002) Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 100:1611–1618PubMed

22.

Laughlin MJ, Eapen M, Rubinstein P, Wagner JE, Zhang MJ, Champlin RE, Stevens C, Barker JN, Gale RP, Lazarus HM, Marks DI, van Rood JJ, Scaradavou A, Horowitz MM (2004) Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 351:2265–2275. doi:10.1056/NEJMoa041276 PubMedCrossRef

23.

Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R, Bosi A, Jacobsen N, Ruutu T, de Lima M, Finke J, Frassoni F, Gluckman E (2004) Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 351:2276–2285. doi:10.1056/NEJMoa041469 PubMedCrossRef

24.

Barker JN, Weisdorf DJ, DeFor TE, Blazar BR, McGlave PB, Miller JS, Verfaillie CM, Wagner JE (2005) Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 105:1343–1347. doi:10.1182/blood-2004-07-2717 PubMedCrossRef

25.

Reisner Y, Kapoor N, Kirkpatrick D, Pollack MS, Cunningham-Rundles S, Dupont B, Hodes MZ, Good RA, O’Reilly RJ (1983) Transplantation for severe combined immunodeficiency with HLA-A,B,D,DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood 61:341–348PubMed

26.

Fischer A, Landais P, Friedrich W, Morgan G, Gerritsen B, Fasth A, Porta F, Griscelli C, Goldman SF, Levinsky R et al (1990) European experience of bone-marrow transplantation for severe combined immunodeficiency. Lancet 336:850–854. doi:10.1016/0140-6736(90)92348-L PubMedCrossRef

27.

Buckley RH, Schiff SE, Schiff RI, Markert L, Williams LW, Roberts JL, Myers LA, Ward FE (1999) Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med 340:508–516. doi:10.1056/NEJM199902183400703 PubMedCrossRef

28.

Bachar-Lustig E, Rachamim N, Li HW, Lan F, Reisner Y (1995) Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Nat Med 1:1268–1273 . doi:10.1038/nm1295-1268 PubMedCrossRef

29.

Aversa F, Tabilio A, Terenzi A, Velardi A, Falzetti F, Giannoni C, Iacucci R, Zei T, Martelli MP, Gambelunghe C et al (1994) Successful engraftment of T-cell-depleted haploidentical “three-loci” incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 84:3948–3955PubMed

30.

Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F, Ruggeri L, Barbabietola G, Aristei C, Latini P, Reisner Y, Martelli MF (1998) Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 339:1186–1193. doi:10.1056/NEJM199810223391702 PubMedCrossRef

31.

Aversa F, Velardi A, Tabilio A, Reisner Y, Martelli MF (2001) Haploidentical stem cell transplantation in leukemia. Blood Rev 15:111–119. doi:10.1054/blre.2001.0157 PubMedCrossRef

32.

Martelli MF, Aversa F, Bachar-Lustig E, Velardi A, Reich-Zelicher S, Tabilio A, Gur H, Reisner Y (2002) Transplants across human leukocyte antigen barriers. Semin Hematol 39:48–56. doi:10.1053/shem.2002.29255 PubMedCrossRef

33.

Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S, Felicini R, Falcinelli F, Velardi A, Ruggeri L, Aloisi T, Saab JP, Santucci A, Perruccio K, Martelli MP, Mecucci C, Reisner Y, Martelli MF (2005) Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 23:3447–3454. doi:10.1200/JCO.2005.09.117 PubMedCrossRef

34.

Volpi I, Perruccio K, Tosti A, Capanni M, Ruggeri L, Posati S, Aversa F, Tabilio A, Romani L, Martelli MF, Velardi A (2001) Postgrafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotype-mismatched hematopoietic transplants. Blood 97:2514–2521. doi:10.1182/blood.V97.8.2514 PubMedCrossRef

35.

Perruccio K, Tosti A, Burchielli E, Topini F, Ruggeri L, Carotti A, Capanni M, Urbani E, Mancusi A, Aversa F, Martelli MF, Romani L, Velardi A (2005) Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood 106:4397–4406. doi:10.1182/blood-2005-05-1775 PubMedCrossRef

36.

Comoli P, Labirio M, Basso S, Baldanti F, Grossi P, Furione M, Vigano M, Fiocchi R, Rossi G, Ginevri F, Gridelli B, Moretta A, Montagna D, Locatelli F, Gerna G, Maccario R (2002) Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 99:2592–2598. doi:10.1182/blood.V99.7.2592 PubMedCrossRef

37.

Cudkowicz G, Bennett M (1971) Peculiar immunobiology of bone marrow allografts. II. Rejection of parental grafts by resistant F 1 hybrid mice. J Exp Med 134:1513–1528. doi:10.1084/jem.134.6.1513 PubMedCrossRef

38.

Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295:2097–2100. doi:10.1126/science.1068440 PubMedCrossRef

39.

Lanier LL (2008) Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 9:495–502. doi:10.1038/ni1581 PubMedCrossRef

40.

Gasser S, Raulet DH (2006) Activation and self-tolerance of natural killer cells. Immunol Rev 214:130–142. doi:10.1111/j.1600-065X.2006.00460.x PubMedCrossRef

41.

Yokoyama WM, Kim S (2006) Licensing of natural killer cells by self-major histocompatibility complex class I. Immunol Rev 214:143–154. doi:10.1111/j.1600-065X.2006.00458.x PubMedCrossRef

42.

Parham P (2006) Taking license with natural killer cell maturation and repertoire development. Immunol Rev 214:155–160. doi:10.1111/j.1600-065X.2006.00462.x PubMedCrossRef

43.

Moretta L, Bottino C, Pende D, Vitale M, Mingari MC, Moretta A (2004) Different checkpoints in human NK-cell activation. Trends Immunol 25:670–676. doi:10.1016/j.it.2004.09.008 PubMedCrossRef

44.

Lanier LL (2005) NK cell recognition. Annu Rev Immunol 23:225–274. doi:10.1146/annurev.immunol.23.021704.115526 PubMedCrossRef

45.

Wu J, Song Y, Bakker AB, Bauer S, Spies T, Lanier LL, Phillips JH (1999) An activating immunoreceptor complex formed by NKG2D and DAP10. Science 285:730–732. doi:10.1126/science.285.5428.730 PubMedCrossRef

46.

Jamieson AM, Diefenbach A, McMahon CW, Xiong N, Carlyle JR, Raulet DH (2002) The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 17:19–29. doi:10.1016/S1074-7613(02)00333-3 PubMedCrossRef

47.

Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T (1999) Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285:727–729. doi:10.1126/science.285.5428.727 PubMedCrossRef

48.

Cosman D, Mullberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, Kubin M, Chalupny NJ (2001) ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14:123–133. doi:10.1016/S1074-7613(01)00095-4 PubMedCrossRef

49.

Diefenbach A, Jamieson AM, Liu SD, Shastri N, Raulet DH (2000) Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol 1:119–126. doi:10.1038/77793 PubMedCrossRef

50.

Diefenbach A, Jensen ER, Jamieson AM, Raulet DH (2001) Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413:165–171. doi:10.1038/35093109 PubMedCrossRef

51.

Cerwenka A, Bakker AB, McClanahan T, Wagner J, Wu J, Phillips JH, Lanier LL (2000) Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity 12:721–727. doi:10.1016/S1074-7613(00)80222-8 PubMedCrossRef

52.

Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T (1999) Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci U S A 96:6879–6884. doi:10.1073/pnas.96.12.6879 PubMedCrossRef

53.

Sutherland CL, Chalupny NJ, Schooley K, VandenBos T, Kubin M, Cosman D (2002) UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells. J Immunol 168:671–679PubMed

54.

Kubin M, Cassiano L, Chalupny J, Chin W, Cosman D, Fanslow W, Mullberg J, Rousseau AM, Ulrich D, Armitage R (2001) ULBP1, 2, 3: novel MHC class I-related molecules that bind to human cytomegalovirus glycoprotein UL16, activate NK cells. Eur J Immunol 31:1428–1437. doi:10.1002/1521-4141(200105)31:5<1428::AID-IMMU1428>3.0.CO;2-4 PubMedCrossRef

55.

Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Conte R, Kubin M, Cosman D, Ferrone S, Moretta L, Moretta A (2002) Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 62:6178–6186PubMed

56.

Pessino A, Sivori S, Bottino C, Malaspina A, Morelli L, Moretta L, Biassoni R, Moretta A (1998) Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J Exp Med 188:953–960. doi:10.1084/jem.188.5.953 PubMedCrossRef

57.

Cantoni C, Bottino C, Vitale M, Pessino A, Augugliaro R, Malaspina A, Parolini S, Moretta L, Moretta A, Biassoni R (1999) NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily. J Exp Med 189:787–796. doi:10.1084/jem.189.5.787 PubMedCrossRef

58.

Pende D, Parolini S, Pessino A, Sivori S, Augugliaro R, Morelli L, Marcenaro E, Accame L, Malaspina A, Biassoni R, Bottino C, Moretta L, Moretta A (1999) Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med 190:1505–1516. doi:10.1084/jem.190.10.1505 PubMedCrossRef

59.

Ferlazzo G, Tsang ML, Moretta L, Melioli G, Steinman RM, Munz C (2002) Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med 195:343–351. doi:10.1084/jem.20011149 PubMedCrossRef

60.

Colonna M, Samaridis J (1995) Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells. Science 268:405–408. doi:10.1126/science.7716543 PubMedCrossRef

61.

Uhrberg M, Valiante NM, Shum BP, Shilling HG, Lienert-Weidenbach K, Corliss B, Tyan D, Lanier LL, Parham P (1997) Human diversity in killer cell inhibitory receptor genes. Immunity 7:753–763. doi:10.1016/S1074-7613(00)80394-5 PubMedCrossRef

62.

Vilches C, Parham P (2002) KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol 20:217–251. doi:10.1146/annurev.immunol.20.092501.134942 PubMedCrossRef

63.

Moretta A, Sivori S, Vitale M, Pende D, Morelli L, Augugliaro R, Bottino C, Moretta L (1995) Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural killer cells. J Exp Med 182:875–884. doi:10.1084/jem.182.3.875 PubMedCrossRef

64.

Biassoni R, Pessino A, Malaspina A, Cantoni C, Bottino C, Sivori S, Moretta L, Moretta A (1997) Role of amino acid position 70 in the binding affinity of p50.1 and p58.1 receptors for HLA-Cw4 molecules. Eur J Immunol 27:3095–3099. doi:10.1002/eji.1830271203 PubMedCrossRef

65.

Vales-Gomez M, Reyburn HT, Erskine RA, Strominger J (1998) Differential binding to HLA-C of p50-activating and p58-inhibitory natural killer cell receptors. Proc Natl Acad Sci U S A 95:14326–14331. doi:10.1073/pnas.95.24.14326 PubMedCrossRef

66.

Winter CC, Gumperz JE, Parham P, Long EO, Wagtmann N (1998) Direct binding and functional transfer of NK cell inhibitory receptors reveal novel patterns of HLA-C allotype recognition. J Immunol 161:571–577PubMed

67.

Parham P (2005) MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 5:201–214. doi:10.1038/nri1570 PubMedCrossRef

68.

Saulquin X, Gastinel LN, Vivier E (2003) Crystal structure of the human natural killer cell activating receptor KIR2DS2 (CD158j). J Exp Med 197:933–938. doi:10.1084/jem.20021624 PubMedCrossRef

69.

Stewart CA, Laugier-Anfossi F, Vely F, Saulquin X, Riedmuller J, Tisserant A, Gauthier L, Romagne F, Ferracci G, Arosa FA, Moretta A, Sun PD, Ugolini S, Vivier E (2005) Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci USA 102:13224–13229. doi:10.1073/pnas.0503594102 PubMedCrossRef

70.

Kim S, Poursine-Laurent J, Truscott SM, Lybarger L, Song YJ, Yang L, French AR, Sunwoo JB, Lemieux S, Hansen TH, Yokoyama WM (2005) Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 436:709–713. doi:10.1038/nature03847 PubMedCrossRef

71.

Anfossi N, Andre P, Guia S, Falk CS, Roetynck S, Stewart CA, Breso V, Frassati C, Reviron D, Middleton D, Romagne F, Ugolini S, Vivier E (2006) Human NK cell education by inhibitory receptors for MHC class I. Immunity 25:331–342. doi:10.1016/j.immuni.2006.06.013 PubMedCrossRef

72.

Moretta L, Moretta A (2004) Killer immunoglobulin-like receptors. Curr Opin Immunol 16:626–633. doi:10.1016/j.coi.2004.07.010 PubMedCrossRef

73.

Ciccone E, Pende D, Viale O, Di Donato C, Tripodi G, Orengo AM, Guardiola J, Moretta A, Moretta L (1992) Evidence of a natural killer (NK) cell repertoire for (allo) antigen recognition: definition of five distinct NK-determined allospecificities in humans. J Exp Med 175:709–718. doi:10.1084/jem.175.3.709 PubMedCrossRef

74.

Colonna M, Brooks EG, Falco M, Ferrara GB, Strominger JL (1993) Generation of allospecific natural killer cells by stimulation across a polymorphism of HLA-C. Science 260:1121–1124. doi:10.1126/science.8493555 PubMedCrossRef

75.

Valiante NM, Uhrberg M, Shilling HG, Lienert-Weidenbach K, Arnett KL, D'Andrea A, Phillips JH, Lanier LL, Parham P (1997) Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity 7:739–751. doi:10.1016/S1074-7613(00)80393-3 PubMedCrossRef

76.

Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA (2002) Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 100:1935–1947. doi:10.1182/blood-2002-02-0350 PubMedCrossRef

77.

Velardi A, Ruggeri L, Moretta A, Moretta L (2002) NK cells: a lesson from mismatched hematopoietic transplantation. Trends Immunol 23:438–444. doi:10.1016/S1471-4906(02)02284-6 PubMedCrossRef

78.

Parham P, McQueen KL (2003) Alloreactive killer cells: hindrance and help for haematopoietic transplants. Nat Rev Immunol 3:108–122. doi:10.1038/nri999 PubMedCrossRef

79.

Ruggeri L, Aversa F, Martelli MF, Velardi A (2006) Allogeneic hematopoietic transplantation and natural killer cell recognition of missing self. Immunol Rev 214:202–218. doi:10.1111/j.1600-065X.2006.00455.x PubMedCrossRef

80.

Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K, Urbani E, Negrin RS, Martelli MF, Velardi A (1999) Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 94:333–339PubMed

81.

Karre K (2002) Immunology. A perfect mismatch. Science 295:2029–2031. doi:10.1126/science.1070538 PubMedCrossRef

82.

Ruggeri L, Mancusi A, Capanni M, Urbani E, Carotti A, Aloisi T, Stern M, Pende D, Perruccio K, Burchielli E, Topini F, Bianchi E, Aversa F, Martelli MF, Velardi A (2007) Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 110:433–440. doi:10.1182/blood-2006-07-038687 PubMedCrossRef

83.

Hsu KC, Chida S, Geraghty DE, Dupont B (2002) The killer cell immunoglobulin-like receptor (KIR) genomic region: gene-order, haplotypes and allelic polymorphism. Immunol Rev 190:40–52. doi:10.1034/j.1600-065X.2002.19004.x PubMedCrossRef

84.

Pando MJ, Gardiner CM, Gleimer M, McQueen KL, Parham P (2003) The protein made from a common allele of KIR3DL1 (3DL1*004) is poorly expressed at cell surfaces due to substitution at positions 86 in Ig domain 0 and 182 in Ig domain 1. J Immunol 171:6640–6649PubMed

85.

Thomas R, Yamada E, Alter G, Martin MP, Bashirova AA, Norman PJ, Altfeld M, Parham P, Anderson SK, McVicar DW, Carrington M (2008) Novel KIR3DL1 alleles and their expression levels on NK cells: convergent evolution of KIR3DL1 phenotype variation? J Immunol 180:6743–6750PubMed

86.

Igarashi T, Wynberg J, Srinivasan R, Becknell B, McCoy JP Jr, Takahashi Y, Suffredini DA, Linehan WM, Caligiuri MA, Childs RW (2004) Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood 104:170–177. doi:10.1182/blood-2003-12-4438 PubMedCrossRef

87.

Stern M, Ruggeri L, Mancusi A, Bernardo ME, de Angelis C, Bucher C, Locatelli F, Aversa F, Velardi A (2008) Survival after T-cell depleted haploidentical stem cell transplantation is improved using the mother as donor. Blood 112:708–710. doi:10.1182/blood-2008-02-137521 PubMedCrossRef

88.

Hansasuta P, Dong T, Thananchai H, Weekes M, Willberg C, Aldemir H, Rowland-Jones S, Braud VM (2004) Recognition of HLA-A3 and HLA-A11 by KIR3DL2 is peptide-specific. Eur J Immunol 34:1673–1679. doi:10.1002/eji.200425089 PubMedCrossRef

89.

Cooley S, McCullar V, Wangen R, Bergemann TL, Spellman S, Weisdorf DJ, Miller JS (2005) KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood 106:4370–4376. doi:10.1182/blood-2005-04-1644 PubMedCrossRef

90.

Davies SM, Ruggieri L, DeFor T, Wagner JE, Weisdorf DJ, Miller JS, Velardi A, Blazar BR (2002) Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood 100:3825–3827. doi:10.1182/blood-2002-04-1197 PubMedCrossRef

91.

Lowe EJ, Turner V, Handgretinger R, Horwitz EM, Benaim E, Hale GA, Woodard P, Leung W (2003) T-cell alloreactivity dominates natural killer cell alloreactivity in minimally T-cell-depleted HLA-non-identical paediatric bone marrow transplantation. Br J Haematol 123:323–326. doi:10.1046/j.1365-2141.2003.04604.x PubMedCrossRef

92.

Bornhauser M, Schwerdtfeger R, Martin H, Frank KH, Theuser C, Ehninger G (2004) Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors. Blood 103:2860–2861 author reply 2862. doi:10.1182/blood-2003-11-3893 PubMedCrossRef

93.

Farag SS, Bacigalupo A, Eapen M, Hurley C, Dupont B, Caligiuri MA, Boudreau C, Nelson G, Oudshoorn M, van Rood J, Velardi A, Maiers M, Setterholm M, Confer D, Posch PE, Anasetti C, Kamani N, Miller JS, Weisdorf D, Davies SM (2006) The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Transplant 12:876–884. doi:10.1016/j.bbmt.2006.05.007 PubMedCrossRef

94.

Hsu KC, Gooley T, Malkki M, Pinto-Agnello C, Dupont B, Bignon JD, Bornhauser M, Christiansen F, Gratwohl A, Morishima Y, Oudshoorn M, Ringden O, van Rood JJ, Petersdorf E (2006) KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol Blood Marrow Transplant 12:828–836. doi:10.1016/j.bbmt.2006.04.008 PubMedCrossRef

95.

Kroger N, Binder T, Zabelina T, Wolschke C, Schieder H, Renges H, Ayuk F, Dahlke J, Eiermann T, Zander A (2006) Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation. Transplantation 82:1024–1030. doi:10.1097/01.tp.0000235859.24513.43 PubMedCrossRef

96.

Yabe T, Matsuo K, Hirayasu K, Kashiwase K, Kawamura-Ishii S, Tanaka H, Ogawa A, Takanashi M, Satake M, Nakajima K, Tokunaga K, Inoko H, Saji H, Ogawa S, Juji T, Sasazuki T, Kodera Y, Morishima Y (2008) Donor killer immunoglobulin-like receptor (KIR) genotype-patient cognate KIR ligand combination and antithymocyte globulin preadministration are critical factors in outcome of HLA-C-KIR ligand-mismatched T cell-replete unrelated bone marrow transplantation. Biol Blood Marrow Transplant 14:75–87. doi:10.1016/j.bbmt.2007.09.012 PubMedCrossRef

97.

Dawson MA, Spencer A (2005) Successful use of haploidentical stem-cell transplantation with KIR mismatch as initial therapy for poor-risk myelodysplastic syndrome. J Clin Oncol 23:4473–4474. doi:10.1200/JCO.2005.01.3581 PubMedCrossRef

98.

Giebel S, Locatelli F, Lamparelli T, Velardi A, Davies S, Frumento G, Maccario R, Bonetti F, Wojnar J, Martinetti M, Frassoni F, Giorgiani G, Bacigalupo A, Holowiecki J (2003) Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 102:814–819. doi:10.1182/blood-2003-01-0091 PubMedCrossRef

99.

Beelen DW, Ottinger HD, Ferencik S, Elmaagacli AH, Peceny R, Trenschel R, Grosse-Wilde H (2005) Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias. Blood 105:2594–2600. doi:10.1182/blood-2004-04-1441 PubMedCrossRef

100.

Elmaagacli AH, Ottinger H, Koldehoff M, Peceny R, Steckel NK, Trenschel R, Biersack H, Grosse-Wilde H, Beelen DW (2005) Reduced risk for molecular disease in patients with chronic myeloid leukemia after transplantation from a KIR-mismatched donor. Transplantation 79:1741–1747. doi:10.1097/01.TP.0000164500.16052.3C PubMedCrossRef

101.

Kroger N, Shaw B, Iacobelli S, Zabelina T, Peggs K, Shimoni A, Nagler A, Binder T, Eiermann T, Madrigal A, Schwerdtfeger R, Kiehl M, Sayer HG, Beyer J, Bornhauser M, Ayuk F, Zander AR, Marks DI (2005) Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. Br J Haematol 129:631–643. doi:10.1111/j.1365-2141.2005.05513.x PubMedCrossRef

102.

Leung W, Iyengar R, Turner V, Lang P, Bader P, Conn P, Niethammer D, Handgretinger R (2004) Determinants of antileukemia effects of allogeneic NK cells. J Immunol 172:644–650PubMed

103.

Leung W, Iyengar R, Triplett B, Turner V, Behm FG, Holladay MS, Houston J, Handgretinger R (2005) Comparison of killer Ig-like receptor genotyping and phenotyping for selection of allogeneic blood stem cell donors. J Immunol 174:6540–6545PubMed

104.

Dupont B, Hsu KC (2004) Inhibitory killer Ig-like receptor genes and human leukocyte antigen class I ligands in haematopoietic stem cell transplantation. Curr Opin Immunol 16:634–643. doi:10.1016/j.coi.2004.07.013 PubMedCrossRef

105.

Hsu KC, Keever-Taylor CA, Wilton A, Pinto C, Heller G, Arkun K, O’Reilly RJ, Horowitz MM, Dupont B (2005) Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 105:4878–4884. doi:10.1182/blood-2004-12-4825 PubMedCrossRef

106.

Hsu KC, Pinto-Agnello C, Gooley T, Malkki M, Dupont B, Petersdorf EW (2007) Hematopoietic stem cell transplantation: killer immunoglobulin-like receptor component. Tissue Antigens 69(Suppl 1):42–45. doi:10.1111/j.1399-0039.2006.759_5.x PubMedCrossRef

107.

Miller JS, Cooley S, Parham P, Farag SS, Verneris MR, McQueen KL, Guethlein LA, Trachtenberg EA, Haagenson M, Horowitz MM, Klein JP, Weisdorf DJ (2007) Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood 109:5058–5061. doi:10.1182/blood-2007-01-065383 PubMedCrossRef

108.

Verheyden S, Schots R, Duquet W, Demanet C (2005) A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation. Leukemia 19:1446–1451. doi:10.1038/sj.leu.2403839 PubMedCrossRef

109.

De Santis D, Bishara A, Witt CS, Nagler A, Brautbar C, Slavin S, Christiansen FT (2005) Natural killer cell HLA-C epitopes and killer cell immunoglobulin-like receptors both influence outcome of mismatched unrelated donor bone marrow transplants. Tissue Antigens 65:519–528. doi:10.1111/j.1399-0039.2005.00396.x PubMedCrossRef

110.

Cook M, Briggs D, Craddock C, Mahendra P, Milligan D, Fegan C, Darbyshire P, Lawson S, Boxall E, Moss P (2006) Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation. Blood 107:1230–1232. doi:10.1182/blood-2005-03-1039 PubMedCrossRef

111.

Chen C, Busson M, Rocha V, Appert ML, Lepage V, Dulphy N, Haas P, Socie G, Toubert A, Charron D, Loiseau P (2006) Activating KIR genes are associated with CMV reactivation and survival after non-T-cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders. Bone Marrow Transplant 38:437–444. doi:10.1038/sj.bmt.1705468 PubMedCrossRef

112.

Cook MA, Milligan DW, Fegan CD, Darbyshire PJ, Mahendra P, Craddock CF, Moss PA, Briggs DC (2004) The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia. Blood 103:1521–1526. doi:10.1182/blood-2003-02-0438 PubMedCrossRef

113.

Bishara A, De Santis D, Witt CC, Brautbar C, Christiansen FT, Or R, Nagler A, Slavin S (2004) The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. Tissue Antigens 63:204–211. doi:10.1111/j.0001-2815.2004.00182.x PubMedCrossRef

114.

Sun JY, Gaidulis L, Dagis A, Palmer J, Rodriguez R, Miller MM, Forman SJ, Senitzer D (2005) Killer Ig-like receptor (KIR) compatibility plays a role in the prevalence of acute GVHD in unrelated hematopoietic cell transplants for AML. Bone Marrow Transplant 36:525–530. doi:10.1038/sj.bmt.1705089 PubMedCrossRef

115.

McQueen KL, Dorighi KM, Guethlein LA, Wong R, Sanjanwala B, Parham P (2007) Donor–recipient combinations of group A and B KIR haplotypes and HLA class I ligand affect the outcome of HLA-matched, sibling donor hematopoietic cell transplantation. Hum Immunol 68:309–323. doi:10.1016/j.humimm.2007.01.019 PubMedCrossRef

Titel: Clinical impact of natural killer cell reconstitution after allogeneic hematopoietic transplantation
verfasst von: Andrea Velardi
Loredana Ruggeri
Antonella Mancusi
Emanuela Burchielli
Katia Perruccio
Franco Aversa
Massimo F. Martelli
on behalf of the Immunobiology Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
Publikationsdatum: 01.12.2008
Verlag: Springer-Verlag
Erschienen in: Seminars in Immunopathology / Ausgabe 4/2008
Print ISSN: 1863-2297
Elektronische ISSN: 1863-2300
DOI: https://doi.org/10.1007/s00281-008-0136-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2008

Adoptive precursor cell therapy to enhance immune reconstitution after hematopoietic stem cell transplantation in mouse and man

The immunopathology of thymic GVHD

The long road to the thymus: the generation, mobilization, and circulation of T-cell progenitors in mouse and man

Lymphoid reconstitution following hematopoietic stem cell transplantation

Strategies for reconstituting and boosting T cell-based immunity following haematopoietic stem cell transplantation: pre-clinical and clinical approaches